TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00613431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Some subjects will receive matching placebo instead of CS-8080.
Study: NCT02471313
Drug: [18F] FMISO
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\] Fluromisonidazole, 1 h-(3-\[18F\]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of \[18F\] FMISO PET imaging post TACE procedure.
Study: NCT00529269
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02850978
Drug: Spiolto
Normalized name: Stiolto
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00844103
Drug: AZD8566
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
Study: NCT00844103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml oral solution administered once a day over 10 days.
Study: NCT01649713
Drug: Fluval AB vaccination
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with Fluval AB suspension for injection
Study: NCT00561522
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
Study: NCT03020407
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
Study: NCT03020407
Drug: Vasopressor
Normalized name: Vasopressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
Study: NCT03129542
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses taken every 8 hours.
Study: NCT00363311
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01080417
Drug: Mycophenolate Mofetil Capsule 250 mg
Normalized name: mycophenolate mofetil Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study: NCT02629861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
Study: NCT01685684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, divided into 2 doses, q12h
Study: NCT01629615
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
Study: NCT00895830
Drug: APD405
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT03973957
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
Study: NCT00895830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00707473
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03658850
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
Study: NCT04442269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01558388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vaginal tablet daily for 10 days.
Study: NCT04729790
Drug: PRIM-DJ2727
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral FMT capsules
Study: NCT03005340
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 20 mg
Study: NCT03005340
Drug: Treatment BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
Study: NCT00570843
Drug: New PEG based artificial tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
Study: NCT00570843
Drug: Optive
Normalized name: optive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
Study: NCT01850953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02108886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: empty capsule filled with sugar
Study: NCT02239926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01334554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active drug
Study: NCT04099277
Drug: LY3435151
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02393859
Drug: Vincrisitne
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/m\^2/day IV on Days 1 and 6
Study: NCT02393859
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 g/m\^2 IV over 36 hours on Day 1
Study: NCT04754763
Drug: Dentin-Bonding Agents
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.
Study: NCT04032821
Drug: Alkotinib（300mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. First empty stomach, after the meal.2. After eating first, after fasting.
Study: NCT01720030
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy to safeguard blinding
Study: NCT00527228
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03423121
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given four capsules of the placebo twice daily.
Study: NCT03568812
Drug: Rillus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
Study: NCT00692003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg Zonisamide Placebo; \>= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)
Study: NCT03289143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo doses of Semorinemab given intravenously (IV).
Study: NCT03289143
Drug: [18F]GTP1
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Study: NCT00305877
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00140023
Drug: Azithromycin microspheres 2.0 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05017870
Drug: KSR-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: (0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
Study: NCT05017870
Drug: KSR-004
Approvals — FDA: no, EMA: no, PMDA: no
Description: (0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
Study: NCT05017870
Drug: KSR-001-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: KSR-001-02
Study: NCT05017870
Drug: KSR-001-03
Approvals — FDA: no, EMA: no, PMDA: no
Description: KSR-001-03
Study: NCT00222976
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
Study: NCT03633357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take two placebo tablets daily, for seven days.
Study: NCT00077974
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
Study: NCT00030147
Drug: Transdermal Estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 microgram per day transdermal estradiol
Study: NCT00030147
Drug: Placebo skin patch and placebo tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
Study: NCT02248896
Drug: Other angiotensin-receptor blockers (ARBs)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02248896
Drug: Angiotensin-converting enzyme inhibitors (ACEIs)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02248896
Drug: Other major antihypertensive medication classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
Study: NCT01056614
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01874392
Drug: Investigational inhaled insulin (Technosphere)
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: by MannKind Corp. IND 61,729
Study: NCT02805790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of treatment with placebo administered once daily subcutaneously
Study: NCT04567524
Drug: LYN-005
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
Study: NCT04274595
Drug: Generic antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days
Study: NCT00057564
Drug: A (Thalidomide + Dexamethasone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 50mg/day + Dexamethasone 40mg
Study: NCT00057564
Drug: B (Placebo + Dexamethasone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Dexamethasone 40mg
Study: NCT02318017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02953184
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35mg/m2 iv drop during the first 4 cycles every three week
Study: NCT02953184
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/m2 IV drop during the first 4 cycles every three week
Study: NCT02953184
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
Study: NCT00054587
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m², D1 and every 3 weeks
Study: NCT00054587
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m², D1 and every 3 weeks
Study: NCT01008618
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
Study: NCT01008618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
Study: NCT03509961
Drug: Myeloablative allogeneic HCT with a non-TBI conditioning regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant
Study: NCT01385592
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01385592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01130181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02731287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
Study: NCT01291108
Drug: AGN-210669
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
Study: NCT00414570
Drug: [18]F-FLT PET scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of \[18\]F-FLT radiopharmaceutical followed by PET imaging.
Study: NCT01175343
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02472249
Drug: Norepinephrine intra-arteriel/hepatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds..
Study: NCT02604459
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl per protocol
Study: NCT01138475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive substance, one capsule daily for 6 weeks
Study: NCT00893841
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02132403
Drug: BTH1704
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
Study: NCT04389073
Drug: Cyclophosphamide 50 mg
Normalized name: cyclophosphamide 50 MG
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT04389073
Drug: Capecitabine 500Mg Oral Tablet
Normalized name: Capecitabine 500mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg three times a day. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT01951053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.
Study: NCT02539550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02745873
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
Study: NCT03394989
Drug: Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Normalized name: Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator Arm: Dry powder inhaler
Study: NCT01203709
Drug: low dose combination of MMF and Tac
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
Study: NCT04255771
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use a placebo as a comparison
Study: NCT03997864
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
Study: NCT00437749
Drug: CBT-1
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
Study: NCT00246363
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (milk thistle)
Study: NCT00246363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04201080
Drug: Part A: TRV250-20mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV250 SC Injections
Study: NCT03695887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive comparator
Study: NCT01132482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving placebo will have sham dose escalation to maintain blinding.
Study: NCT01763424
Drug: Calcipotriol plus Nicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
Study: NCT04201080
Drug: Part B: TRV250 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2of3 TRV250 SC injections
Study: NCT04409834
Drug: Unfractionated Heparin IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an aPTT of 1.5-2.5 times the control as per institutional therapeutic target for treatment of VTE
Study: NCT04409834
Drug: Unfractionated heparin SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5,000 units administered subcutaneous three times daily
Study: NCT04201080
Drug: Part B: TRV250 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 3of3 TRV250 SC injections
Study: NCT04201080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC injections
Study: NCT00769054
Drug: Isotonic NaCl
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local Infiltration with NaCl
Study: NCT02345733
Drug: Antibiotic cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
Study: NCT01400009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Placebo made of Lactose 100 mg
Study: NCT04055753
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m2, IV over 5-15 min OR Continuous infusion over 48-72 hours
Study: NCT00445094
Drug: Comparator: amikacin / Duration of Treatment: 3 Days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00445094
Drug: Comparator: tazocin / Duration of Treatment: 3 Days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01497197
Drug: GONAL-f®
Approvals — FDA: no, EMA: no, PMDA: no
Description: GONAL f® 300 international units \[IU\] per day as subcutaneous injection using liquid pen.
Study: NCT01497197
Drug: Luveris®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
Study: NCT01114737
Drug: Sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
Study: NCT01114737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
Study: NCT02735018
Drug: Epinephrine 1:100,000
Normalized name: articaine HCl 4 % / epinephrine 1:100,000 Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferior alveolar nerve block with Epinephrine 1:100.000
Study: NCT02735018
Drug: Epinephrine 1:200,000
Normalized name: articaine HCl 4 % / epinephrine 1:200,000 Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferior alveolar nerve block with Epinephrine 1:200.000
Study: NCT00457392
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily by oral capsules in a continuous regimen
Study: NCT03991910
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.
Study: NCT02820896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single or multiple doses of RO7105705 matching placebo IV.
Study: NCT00696033
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazépam placebo or Diazépam placebo
Study: NCT02820896
Drug: RO7105705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single or multiple doses of RO7105705 IV or SC.
Study: NCT04457986
Drug: Intravenous patient controlled analgesia (IV-PCA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive intravenous patient controlled analgesia with tramadol